SynthesisFrontiers in immunology2023
Preoperative systemic immune-inflammation index as a prognostic indicator for patients with urothelial carcinoma.
Synthesis in Frontiers in immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Prognostic value of preoperative systemic immune-inflammation index in patients with bladder cancer undergoing radical cystectomy: a systematic review and meta-analysis.Frontiers in oncology · 2026Pooled it
- Prognostic value of systemic immune-inflammation index in patients with metastatic renal cell carcinoma treated with systemic therapy: a meta-analysis.Frontiers in oncology · 2024Pooled it
- Prognostic significance of systemic immune inflammation index in patients with urothelial carcinoma: a systematic review and meta-analysis.Frontiers in oncology · 2024Pooled it
- Cancer risk and mortality assessment in the overweight population: evaluation of single and integrated models based on inflammatory markers.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Article
- Association between the systemic immune-inflammation index within 1 h after birth and the risk of neonatal respiratory distress syndrome in preterm infants.BMC pediatrics · 2026Article
- Article
- Article
- Association of Exposure to Brominated Flame Retardants with Hyperuricemia: A Mediation Analysis of Inflammatory Factors.Current pharmaceutical design · 2026Article
- TIMP1 expression in colorectal cancer: Linking prognosis, tumor immunity and molecular pathways.Oncology letters · 2026Article
- Association of immuno-inflammatory biomarkers with response to neoadjuvant chemotherapy and prognosis in HER2-positive breast cancer: dual-center clinical evidence.Frontiers in immunology · 2026Article
- Diagnostic value of cellular inflammatory markers in CNS tumor patients undergoing glucocorticoid therapy.Frontiers in oncology · 2026Article
- Relationship Between Systemic Immune-Inflammation Index and In-Hospital Mortality in Sepsis Combined With Chronic Obstructive Pulmonary Disease Modified by Mechanical Ventilation.The clinical respiratory journal · 2025Article
- Assessment of Mortality Risk in Patients With Community-Acquired Pneumonia: Role of Novel Inflammatory Biomarkers.Journal of clinical laboratory analysis · 2025Article
- Systemic immune-inflammation index and serum lactate dehydrogenase predict the prognosis of non-metastatic nasopharyngeal carcinoma patients receiving intensity-modulated radiotherapy.Scientific reports · 2025Article
- Observational
- The Clinical Value of the Combined Detection of Systemic Immune-Inflammation Index (SII), Systemic Inflammation Response Index (SIRI), and Prognostic Nutritional Index (PNI) in Early Diagnosis of Gastric Cancer.Journal of inflammation research · 2025Article
- Peripheral blood immunoinflammatory biomarkers: prospective predictors of postoperative long-term survival and chronic postsurgical pain in breast cancer.Frontiers in immunology · 2025Article
- Clinical Significance of the Serum 3'tRF-AlaAGC, Neutrophil to High-Density Lipoprotein Ratio, and Lymphocyte-to-Monocyte Ratio in Breast Cancer with Lymph Node Metastasis.Journal of inflammation research · 2025Article
- Article
- Identification of an inflammation-related risk signature for prognosis and immunotherapeutic response prediction in bladder cancer.Scientific reports · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The systemic immune-inflammation index (SII) is a cost-efficient indicator for carcinoma prognosis. However, its utility in urothelial carcinoma (UC) prognosis is disputed. This meta-analysis aims to assess SII's prognostic value in UC. Methods: A thorough search of databases including PubMed, Web of Science, Embase, Cochrane Library, and Scopus, was conducted to find studies until January 11, 2023. Eligibility criteria were applied to select studies. Hazard ratios (HRs) and 95% confidence intervals (CIs) were extracted from selected studies and compiled in a meta-analysis to gauge SII's association with survival outcomes such as overall survival (OS), cancer-specific survival (CSS), recurrence-free survival (RFS), and progression-free survival (PFS). Results: This analysis includes 19 studies with 12505 UC patients. It was found that high SII significantly correlated with worse OS in UC patients (HR 1.430, 95% CI 1.237-1.653, P<0.001). High SII values also linked with poorer CSS (HR 1.913, 95% CI 1.473-2.485, P<0.001), RFS (HR 1.240, 95% CI 1.097-1.403, P=0.001), and PFS (HR 1.844, 95% CI 1.488-2.284, P<0.001) compared to low SII values. Subgroup analysis revealed SII's consistent prognostic value in UC across races, carcinoma types, sample sizes, and SII cut-off values, suggesting its potential as a prognostic indicator in UC patients. Conclusion: Current evidence suggests SII as a promising, cost-efficient predictor in UC patients. This meta-analysis indicates SII's potential as a valuable prognostic tool in UC patients. Systematic review registration: https://www.crd.york.ac.uk/PROSPERO/display_record.php?RecordID=307643, identifier CRD42022307643.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.